Real-world enfortumab vedotin dose reductions reduced treatment interruptions without significantly affecting OS in advanced urothelial carcinoma.
Evaluating the Advantages of Upfront Enfortumab Vedotin Dose Reduction in Urothelial Cancer
Ryan D. Chow, MD, discusses real-world data showing that upfront enfortumab vedotin dose reduction can improve tolerability without affecting survival.
Ryan D. Chow, MD, PhD, Ronac Mamtani, MD, MSCE, and Ramy Sedhom, MD, spotlight a real-world analysis of upfront enfortumab vedotin dose reduction in bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5